Published in BMJ on April 14, 2014
Monitor System for the Safety of Dabigatran Treatment (MISSION-AF) | NCT02414035
Efficacy of a Didactic Intervention in Anticoagulated Patients (TAOPE Study) (TAOPE) | NCT03647254
Effect of heart rate control on coagulation status in patients of rheumatic mitral stenosis with atrial fibrillation - A pilot study. Indian Heart J (2015) 0.81
Management of antithrombotic therapy during cardiac implantable device surgery. J Arrhythm (2016) 0.77
12/15-Lipoxygenase Inhibition or Knockout Reduces Warfarin-Associated Hemorrhagic Transformation After Experimental Stroke. Stroke (2017) 0.76
Atrial fibrillation ablation and left appendage closure in heart failure patients. Curr Opin Cardiol (2015) 0.75
Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. Drug Saf (2016) 0.75
VAD therapy 20/20: moving beyond the myopic view of a nascent therapy. Ann Cardiothorac Surg (2014) 0.75
Analytical Management of Patients Undergoing Oral Anticoagulant Therapy Could Have a Strong Impact on Clinical Outcomes: A Follow-up Study. Cardiol Ther (2017) 0.75
Diagnostic yield of external loop recording in patients with acute ischemic stroke or TIA. J Neurol (2015) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke (1991) 22.23
Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation (1998) 19.93
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (2013) 12.44
Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med (2007) 10.87
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet (1989) 10.18
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med (1992) 9.71
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80
Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med (1987) 8.09
A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost (1993) 7.92
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation (2011) 6.47
Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.88
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med (2012) 5.56
Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet (1994) 5.37
Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology (1978) 5.37
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol (2011) 5.06
Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med (2008) 4.83
Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA (2011) 4.73
Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation (2013) 4.60
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33
Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA (2003) 4.13
Stroke severity in atrial fibrillation. The Framingham Study. Stroke (1996) 4.11
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. Circ J (2012) 3.70
Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J (2012) 3.66
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol (2012) 3.55
Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation (2012) 3.47
Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med (1998) 3.27
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol (2013) 3.13
Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol (2012) 3.12
Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J (2006) 3.05
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke (2012) 3.02
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med (2013) 2.84
Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart (2001) 2.78
Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72
Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation (2011) 2.66
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64
Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes (2012) 2.61
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost (2012) 2.61
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J (2010) 2.46
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J (2011) 2.31
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J (2013) 2.27
Dabigatran and postmarketing reports of bleeding. N Engl J Med (2013) 2.15
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet (2009) 2.07
Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. JAMA (1985) 2.00
Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc (2008) 1.97
Feasibility of closed-chest ligation of the left atrial appendage in humans. Heart Rhythm (2010) 1.89
Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med (2011) 1.82
Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients. Heart (2013) 1.65
Occurrence of hemispheric and retinal ischemia in atrial fibrillation compared with carotid stenosis. Stroke (2002) 1.61
Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res (2008) 1.47
Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open (2013) 1.40
Incident atrial fibrillation among Asians, Hispanics, blacks, and whites. Circulation (2013) 1.35
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov (2010) 1.33
Preventing stroke in patients with atrial fibrillation. JAMA (1999) 1.22
Left atrial appendage closure: a percutaneous transcatheter approach for stroke prevention in atrial fibrillation. Eur Heart J (2011) 1.13
Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost (2011) 1.12
Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke (2012) 1.10
Reversal of antithrombotic agents. Am J Hematol (2012) 1.05
Association of atrial fibrillation with mortality and disability after ischemic stroke. Neurology (2013) 0.99
Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost (1996) 0.94
Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One (2013) 0.93
Pathophysiological determinants of worse stroke outcome in atrial fibrillation. Cerebrovasc Dis (2010) 0.92
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J (2013) 0.92
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. Circ Cardiovasc Qual Outcomes (2013) 0.83
Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation Study. The Stroke Prevention in Atrial Fibrillation Investigators. Stroke (1990) 0.81
Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects. Int J Clin Pharmacol Ther (2011) 0.80
Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans. Xenobiotica (2012) 0.78
Fibrinopeptide A (FPA) levels in atrial fibrillation and the effects of heparin administration. Jpn Circ J (1988) 0.76
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J (2011) 2.31
Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. Heart Rhythm (2013) 2.22
Device therapy in heart failure patients with chronic kidney disease. J Am Coll Cardiol (2011) 1.59
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J (2013) 1.53
Atrial fibrillation among Medicare beneficiaries hospitalized with sepsis: incidence and risk factors. Am Heart J (2013) 1.43
Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation (2010) 1.31
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc (2013) 1.26
Extent of and reasons for nonuse of implantable cardioverter defibrillator devices in clinical practice among eligible patients with left ventricular systolic dysfunction. Circ Cardiovasc Qual Outcomes (2011) 1.24
Retrograde ascending aortic dissection as an early complication of thoracic endovascular aortic repair. J Vasc Surg (2012) 1.22
Remote monitoring of implantable cardioverter defibrillators versus quarterly device interrogations in clinic: results from a randomized pilot clinical trial. J Cardiovasc Electrophysiol (2009) 1.19
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc (2013) 1.15
Cerebral magnetic resonance findings in asymptomatic patients after atrial fibrillation catheter ablation: cause for alarm or further study? J Cardiovasc Electrophysiol (2011) 1.06
Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. J Interv Card Electrophysiol (2013) 1.02
Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes (2013) 0.97
QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy. JAMA (2013) 0.96
Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure. J Am Heart Assoc (2013) 0.94
Rationale and design of the Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository. Am Heart J (2009) 0.93
Surgical Maze procedure as a treatment for atrial fibrillation: a meta-analysis of randomized controlled trials. Cardiovasc Ther (2010) 0.91
Exercise training and implantable cardioverter-defibrillator shocks in patients with heart failure: results from HF-ACTION (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing). JACC Heart Fail (2013) 0.91
Impact of using a telescoping-support catheter system for left ventricular lead placement on implant success and procedure time of cardiac resynchronization therapy. Pacing Clin Electrophysiol (2013) 0.89
The S1103Y cardiac sodium channel variant is associated with implantable cardioverter-defibrillator events in blacks with heart failure and reduced ejection fraction. Circ Cardiovasc Genet (2011) 0.89
Predictors of mortality in patients with chronic kidney disease and an implantable defibrillator: an EPGEN substudy. Europace (2011) 0.87
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J (2013) 0.86
Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. Am J Med (2013) 0.86
Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. Am Heart J (2012) 0.86
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med (2013) 0.86
Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fraction. Am J Ther (2010) 0.84
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. Circ Cardiovasc Qual Outcomes (2013) 0.83
Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement? Europace (2011) 0.83
Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death: A Science Advisory From the American Heart Association. Circulation (2016) 0.82
Comparative effectiveness of cardiac resynchronization therapy with an implantable cardioverter-defibrillator versus defibrillator therapy alone: a cohort study. Ann Intern Med (2014) 0.82
Intraoperative Magnesium Administration Does Not Reduce Postoperative Atrial Fibrillation After Cardiac Surgery. Anesth Analg (2015) 0.82
Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation (2017) 0.82
Localization of pacing and defibrillator leads using standard x-ray views is frequently inaccurate and is not reproducible. J Interv Card Electrophysiol (2015) 0.81
Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. J Am Heart Assoc (2013) 0.81
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. Am Heart J (2012) 0.81
Cardiac conduction system disease after transcatheter aortic valve replacement. Am Heart J (2012) 0.81
International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. Am Heart J (2012) 0.81
Do omega-3 fatty acids prevent atrial fibrillation after open heart surgery? A meta-analysis of randomized controlled trials. Clinics (Sao Paulo) (2011) 0.80
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J (2013) 0.79
Management of postoperative atrial fibrillation and subsequent outcomes in contemporary patients undergoing cardiac surgery: insights from the Society of Thoracic Surgeons CAPS-Care Atrial Fibrillation Registry. Clin Cardiol (2013) 0.79
Preprocedural ECG-gated computed tomography for prevention of complications during lead extraction. Pacing Clin Electrophysiol (2014) 0.79
Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial). Am J Cardiol (2011) 0.78
Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure. Expert Rev Cardiovasc Ther (2015) 0.77
Prognostic validation of an algorithm to convert myocardial perfusion SPECT imaging data from a 12-segment model to a 17-segment model. J Nucl Cardiol (2009) 0.77
Completion of guideline-recommended initial evaluation of atrial fibrillation. Clin Cardiol (2012) 0.77
Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. J Thromb Thrombolysis (2008) 0.77
Left atrial remodeling: shape before size? J Cardiovasc Electrophysiol (2013) 0.75
ECG interpretation in ST-elevation myocardial infarction: pattern recognition or caliper measurements? Heart (2008) 0.75
Atrial fibrillation and stroke: it's not necessarily all about the rhythm. Heart Rhythm (2011) 0.75
Putting risk prediction in atrial fibrillation into perspective. Eur Heart J (2012) 0.75
Risk assessment in atrial fibrillation: not all factors are created equal. Europace (2013) 0.75
For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding. Evid Based Med (2012) 0.75
Response to letter regarding article, “sustained ventricular tachycardia and ventricular fibrillation complicating non–ST-segment elevation acute coronary syndromes”. Circulation (2013) 0.75
Cardiac resynchronization therapy in patients with renal dysfunction: keep calm and carry on. J Cardiovasc Electrophysiol (2014) 0.75
Optimal utilization and management of implanted cardiac rhythm devices in patients hospitalized for heart failure. Heart Fail Clin (2013) 0.75
Relationship of sustained ventricular tachyarrhythmias to outcomes in patients undergoing primary percutaneous coronary intervention with varying underlying baseline risk. Am Heart J (2011) 0.75
Highlights from American Heart Association, November 4-7, 2007, Orlando, Florida, USA. Late-breaking trials summary. Am Heart J (2008) 0.75
Mandatory diagnostic screening tests to individualize therapy: a curious paradox. Circ Arrhythm Electrophysiol (2012) 0.75
Implantable cardioverter-defibrillator implementation in acute heart failure syndromes: unanswered questions. Heart Fail Rev (2011) 0.75
The potential role of nonpharmacologic electrophysiology-based interventions in improving outcomes in patients hospitalized for heart failure. Heart Fail Clin (2013) 0.75
Optimal management of Riata leads with no known electrical abnormalities or externalization: a decision analysis. J Cardiovasc Electrophysiol (2014) 0.75
Validation of non-contact and point-to-point mapping in a single electroanatomic map. Europace (2013) 0.75
Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants? J Thromb Thrombolysis (2016) 0.75
Cardiac implantable electronic device removal in patients with left ventricular assist device associated infections. J Cardiovasc Electrophysiol (2014) 0.75